PT  - JOURNAL ARTICLE
AU  - Nichols, Emma Hitt
ED  - Eisenhauer, Elizabeth A.
TI  - Antiangiogenics in Ovarian Cancer: Where are We Now?
DP  - 2012  01
TA  - MD Conference Express
PG  - 28--29
VI  - 12
IP  - 15
4099  - http://mdc.sagepub.com/content/12/15/28.short
4100  - http://mdc.sagepub.com/content/12/15/28.full
AB  - Vascular Endothelial Growth Factor (VEGF) promotes ascites and effusions in ovarian cancer [Byrne AT et al. Clin Cancer Res 2003], and it is an independent adverse predictor of patient prognosis [Shen GH et al. Br J Cancer 2000]. Bevacizumab, a humanized monoclonal antibody that targets VEGF, has shown single-agent activity in Phase 2 epithelial ovarian cancer trials [Burger RA et al. N Engl J Med 2011]. This article provides an update on the data available from Phase 3 bevacizumab ovarian cancer trials.